ATL1102
- Generic Name
- ATL1102
- Drug Type
- Small Molecule
- Background
ATL1102 is a second-generation antisense inhibitor of CD49d, an immunesystem protein known as VLA-4, an immune cell molecule. It works by entering cells and targeting genes.
- Indication
Investigated for use/treatment in asthma and multiple sclerosis.
A Study of ATL1102 or Placebo in Participants with Non-ambulatory Duchenne Muscular Dystrophy
Phase 2
Terminated
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- First Posted Date
- 2023-07-10
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Percheron Therapeutics
- Target Recruit Count
- 48
- Registration Number
- NCT05938023
- Locations
- 🇦🇺
Royal Childrens Hospital, Melbourne, Australia
🇦🇺Queensland Children's Hospital, South Brisbane, Australia
🇦🇺The Children's Hospital at Westmead, Westmead, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath